The compounds of 11-O-galloylbergenin, 11-O-protocatechuoylbergenin, 11-O-syringylbergenin, epicatechin-3-gallate have higher docking scores than the ligand-protein of SRC, and the compounds of bergenin, epicatechin-3-gallate dock better than the ligand-protein of ESR1, suggesting that AGS has multiple ingredients, multiple targets, and multiple pathways against CRC. This evidence concerns the gene SRC and colorectal carcinoma.